Literature DB >> 31302149

Meeting report: 32nd International Conference on Antiviral Research.

Enzo Tramontano1, Bart Tarbet2, Jessica R Spengler3, Katherine Seley-Radtke4, Chris Meier5, Robert Jordan6, Zlatko Janeba7, Brian Gowen2, Brian Gentry8, José A Esté9, Mike Bray10, Graciela Andrei11, Luis M Schang12.   

Abstract

The 32nd International Conference on Antiviral Research (ICAR), sponsored by the International Society for Antiviral Research (ISAR), was held in Baltimore, Maryland, USA, on May 12-15, 2019. This report gives an overview of the conference on behalf of the Society. It provides a general review of the meeting and awardees, summarizing the presentations, and their main conclusions from the perspective of researchers active in many different areas of antiviral research and development. As in past years, ICAR promoted and showcased the most recent progress in antiviral research, and continued to foster collaborations and interactions in drug discovery and development. The 33rd ICAR will be held in Seattle, Washington, USA, March 30th-April 3rd, 2020.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31302149      PMCID: PMC7105345          DOI: 10.1016/j.antiviral.2019.104550

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  51 in total

1.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.

Authors:  David W Kimberlin; Edward P Acosta; Pablo J Sánchez; Sunil Sood; Vish Agrawal; James Homans; Richard F Jacobs; David Lang; Jose R Romero; Jill Griffin; Gretchen A Cloud; Fred D Lakeman; Richard J Whitley
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

3.  Transmission of Nipah Virus - 14 Years of Investigations in Bangladesh.

Authors:  Birgit Nikolay; Henrik Salje; M Jahangir Hossain; A K M Dawlat Khan; Hossain M S Sazzad; Mahmudur Rahman; Peter Daszak; Ute Ströher; Juliet R C Pulliam; A Marm Kilpatrick; Stuart T Nichol; John D Klena; Sharmin Sultana; Sayma Afroj; Stephen P Luby; Simon Cauchemez; Emily S Gurley
Journal:  N Engl J Med       Date:  2019-05-09       Impact factor: 91.245

4.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Authors:  Eleftherios Michailidis; Andrew D Huber; Emily M Ryan; Yee T Ong; Maxwell D Leslie; Kayla B Matzek; Kamalendra Singh; Bruno Marchand; Ariel N Hagedorn; Karen A Kirby; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

5.  Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand.

Authors:  Wendy C Magee; Kathy A Aldern; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

Review 6.  Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.

Authors:  Marina Caskey; Florian Klein; Michel C Nussenzweig
Journal:  Nat Med       Date:  2019-04-01       Impact factor: 53.440

Review 7.  Tecovirimat: First Global Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2018-09       Impact factor: 11.431

8.  HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways.

Authors:  Fang Guo; Qiong Zhao; Muhammad Sheraz; Junjun Cheng; Yonghe Qi; Qing Su; Andrea Cuconati; Lai Wei; Yanming Du; Wenhui Li; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2017-09-25       Impact factor: 6.823

9.  A single mutation in chikungunya virus affects vector specificity and epidemic potential.

Authors:  Konstantin A Tsetsarkin; Dana L Vanlandingham; Charles E McGee; Stephen Higgs
Journal:  PLoS Pathog       Date:  2007-12       Impact factor: 6.823

10.  Meeting report: 26th International Conference on Antiviral Research.

Authors:  R Anthony Vere Hodge
Journal:  Antiviral Res       Date:  2013-08-21       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.